227 related articles for article (PubMed ID: 34477069)
1. Maculopapular Cutaneous Mastocytosis Successfully Treated with Omalizumab.
Tampouratzi L; Kanni T; Katsantonis J; Douvali T
Acta Dermatovenerol Croat; 2021 Apr; 291(1):60-61. PubMed ID: 34477069
[TBL] [Abstract][Full Text] [Related]
2. Telangiectasia macularis eruptiva perstans: a neglected type of mastocytosis with exclusively cutaneous involvement? A case series.
Michelerio A; Grassi S; Elena C; Croci GA; Boveri E; Bossi G; Brazzelli V
Eur J Dermatol; 2019 Apr; 29(2):174-178. PubMed ID: 30973331
[TBL] [Abstract][Full Text] [Related]
3. Telangiectasia macularis eruptiva perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvement.
Severino M; Chandesris MO; Barete S; Tournier E; Sans B; Laurent C; Apoil PA; Lamant L; Mailhol C; Laroche M; Fraitag S; Hanssens K; Dubreuil P; Hermine O; Paul C; Bulai Livideanu C
J Am Acad Dermatol; 2016 May; 74(5):885-91.e1. PubMed ID: 26899198
[TBL] [Abstract][Full Text] [Related]
4. Telangiectasia macularis eruptiva perstans: more than skin deep.
Watkins CE; Bokor WB; Leicht S; Youngberg G; Krishnaswamy G
Dermatol Reports; 2011 Jan; 3(1):e12. PubMed ID: 25386256
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of omalizumab in Cutaneous Mastocytosis: A case series.
Hinojosa T; Lewis DJ; Vangipuram R; Safeer L; Mui UN; Haley C; Konoplev S; Tyring SK
Dermatol Ther; 2019 May; 32(3):e12848. PubMed ID: 30697883
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications.
Bossi G; Brazzelli V; De Amici M; Pietra D; Raviola C; Naso M; Regalbuto C; Boselli F; Fortina V; Marseglia GL
Ital J Pediatr; 2023 Jan; 49(1):6. PubMed ID: 36639823
[TBL] [Abstract][Full Text] [Related]
7. Telangiectasia macularis eruptiva perstans.
Cohn MS; Mahon MJ
J Am Osteopath Assoc; 1994 Mar; 94(3):246-8. PubMed ID: 8200829
[TBL] [Abstract][Full Text] [Related]
8. A case of omalizumab as a successful treatment for telangiectasia macularis eruptiva perstans.
Mortimore AM; Barsoum R; Lambie D; McMeniman E
Australas J Dermatol; 2022 Feb; 63(1):102-104. PubMed ID: 34314029
[TBL] [Abstract][Full Text] [Related]
9. Acquired bilateral telangiectasia macularis eruptiva perstans: A unique clinical feature of photodamaging rather than a subtype of cutaneous mastocytosis.
Moon HR; Kim YJ; Jung JM; Won CH; Lee MW; Choi JH; Chang SE
J Dermatol; 2017 Nov; 44(11):1276-1280. PubMed ID: 28646532
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the Diagnosis of Cutaneous Mastocytosis.
Brockow K; Bent RK; Schneider S; Spies S; Kranen K; Hindelang B; Kurgyis Z; Broesby-Olsen S; Biedermann T; Grattan CE
Diagnostics (Basel); 2024 Jan; 14(2):. PubMed ID: 38248039
[TBL] [Abstract][Full Text] [Related]
11. [MACULOPAPULAR CUTANEOUS MASTOCYTOSIS HARBORING A KIT MUTATION (ASP419DEL): A CASE REPORT].
Fukaura A; Numata T; Chiyotanda M; Maeda T; Egusa C; Ito T; Harada K; Okubo Y
Arerugi; 2024; 73(2):189-195. PubMed ID: 38522933
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.
Broesby-Olsen S; Vestergaard H; Mortz CG; Jensen B; Havelund T; Hermann AP; Siebenhaar F; Møller MB; Kristensen TK; Bindslev-Jensen C;
Allergy; 2018 Jan; 73(1):230-238. PubMed ID: 28662309
[TBL] [Abstract][Full Text] [Related]
13. The skin in mastocytosis.
Soter NA
J Invest Dermatol; 1991 Mar; 96(3):32S-38S; discussion 38S-39S. PubMed ID: 1672136
[TBL] [Abstract][Full Text] [Related]
14. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
15. Telangiectasia macularis eruptiva perstans: unusual presentation and treatment.
Rishpon A; Matz H; Gat A; Brenner S
Skinmed; 2006; 5(6):300-2. PubMed ID: 17086000
[TBL] [Abstract][Full Text] [Related]
16. Unusual cutaneous findings of urticaria pigmentosa and telangiectasia macularis eruptiva perstans associated with marked myelofibrosis.
Turchin I; Barankin B; Schloss E
Int J Dermatol; 2006 Oct; 45(10):1215-7. PubMed ID: 17040445
[TBL] [Abstract][Full Text] [Related]
17. Reddish-brown macules with telangiectasia and pruritus. Urticaria pigmentosa-telangiectasia macularis eruptiva perstans (TMEP) variant, with systemic mastocytosis.
Parks A; Camisa C
Arch Dermatol; 1988 Mar; 124(3):429-30, 432-3. PubMed ID: 3345092
[No Abstract] [Full Text] [Related]
18. Telangiectasia macularis eruptiva perstans: a rare form of adult mastocytosis.
Costa DL; Moura HH; Rodrigues R; Pineiro-Maceira J; Ramos-E-Silva M
J Clin Aesthet Dermatol; 2011 Oct; 4(10):52-4. PubMed ID: 22010057
[TBL] [Abstract][Full Text] [Related]
19. Solitary mastocytoma presenting in an adult: report and literature review of adult-onset solitary cutaneous mastocytoma with recommendations for evaluation and treatment.
Cohen PR
Dermatol Pract Concept; 2016 Jul; 6(3):31-8. PubMed ID: 27648381
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous mastocytosis in Singapore.
Tay YK; Giam YC
Singapore Med J; 1993 Oct; 34(5):425-9. PubMed ID: 8153691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
